Data / Form D filings / Expanesthetics, Inc
Expanesthetics, Inc: Form D filings
Expanesthetics, Inc, a pharmaceuticals company in Davis, United States, filed 30 Form D notices with the SEC between 2017 and 2024. The latest, on March 4, 2024, reports $234,260 sold of a $234,260 offering to 6 investors.
SpecStream is the live web data engine for teams and agents. It reads every Form D on SEC EDGAR the day it is filed, and this page is that reading. Ask for your own cut (a state, an industry, a size) and new filings arrive in your sheet, CRM, Slack or agent as they land.
Company details from the filing
- Address
- 1450 DREW AVE., SUITE 100, Davis, United States, 95618
- Phone
- (844) 298-7201
- Industry
- Pharmaceuticals
- Entity type
- Corporation
- Incorporated in
- California
- Revenue range
- No Revenues
- Exemptions claimed
- Rule 506(c)
- SEC identifier (CIK)
- 1716170
Form D filings
| Filed | Type | Offering | Sold | Remaining | Investors | First sale | Filing |
|---|---|---|---|---|---|---|---|
| Mar 4, 2024 | New notice | $234,260 | $234,260 | 6 | Dec 4, 2023 | sec.gov | |
| Mar 4, 2024 | New notice | $372,300 | $372,300 | 37 | Oct 9, 2023 | sec.gov | |
| Sep 8, 2023 | New notice | $282,338 | $282,338 | 13 | Jul 5, 2023 | sec.gov | |
| Sep 8, 2023 | New notice | $356,400 | $356,400 | 18 | Feb 2, 2023 | sec.gov | |
| Sep 8, 2023 | New notice | $20,496 | $20,496 | 4 | Jan 25, 2023 | sec.gov | |
| Feb 9, 2023 | New notice | $227,700 | $227,700 | 17 | Dec 1, 2022 | sec.gov | |
| Feb 9, 2023 | New notice | $554,233 | $554,233 | 20 | May 13, 2022 | sec.gov | |
| Jan 7, 2022 | Amendment | $84,857 | $84,857 | 1 | Sep 14, 2021 | sec.gov | |
| Jan 7, 2022 | New notice | $1,292,646 | $1,292,646 | 33 | Dec 22, 2021 | sec.gov | |
| Oct 13, 2021 | New notice | $302,680 | $9,982 | $292,698 | 1 | Sep 14, 2021 | sec.gov |
| Aug 6, 2021 | Amendment | $823,108 | $823,108 | 53 | Apr 30, 2021 | sec.gov | |
| Jun 3, 2021 | New notice | $1,000,000 | $433,367 | $566,633 | 23 | Apr 30, 2021 | sec.gov |
| Jun 2, 2021 | Amendment | $342,640 | $342,640 | 20 | Sep 8, 2020 | sec.gov | |
| Jun 2, 2021 | Amendment | $219,604 | $219,604 | 16 | Sep 9, 2020 | sec.gov | |
| Feb 1, 2021 | Amendment | $289,478 | $289,478 | 15 | Sep 9, 2020 | sec.gov | |
| Oct 15, 2020 | New notice | $239,568 | $239,568 | 14 | Sep 9, 2020 | sec.gov | |
| Oct 15, 2020 | New notice | $15,741,614 | $109,802 | $15,631,812 | 6 | Sep 8, 2020 | sec.gov |
| Sep 10, 2020 | New notice | $260,897 | $260,897 | 22 | Jun 8, 2020 | sec.gov | |
| Sep 10, 2020 | Amendment | $769,091 | $769,091 | 28 | Apr 24, 2019 | sec.gov | |
| Sep 10, 2020 | Amendment | $708,125 | $708,125 | 34 | Oct 31, 2019 | sec.gov | |
| Apr 21, 2020 | Amendment | $1,500,000 | $708,125 | $791,875 | 34 | Oct 31, 2019 | sec.gov |
| Oct 31, 2019 | New notice | $1,500,000 | $0 | $1,500,000 | 0 | Yet to occur | sec.gov |
| Sep 23, 2019 | Amendment | $1,500,000 | $318,870 | $1,181,130 | 10 | Apr 24, 2019 | sec.gov |
| May 14, 2019 | New notice | $500,100 | $106,245 | $393,855 | 3 | Apr 24, 2019 | sec.gov |
| Mar 5, 2019 | New notice | $445,140 | $445,140 | 29 | Jan 20, 2019 | sec.gov | |
| Mar 5, 2019 | Amendment | $1,163,593 | $1,163,593 | 57 | Jul 9, 2018 | sec.gov | |
| Mar 5, 2019 | Amendment | $1,393,561 | $1,393,561 | 48 | Sep 14, 2017 | sec.gov | |
| Aug 14, 2018 | New notice | $1,163,593 | $1,163,593 | 57 | Jul 9, 2018 | sec.gov | |
| Jan 22, 2018 | New notice | $15,750,000 | $601,650 | $15,148,350 | 7 | Sep 14, 2017 | sec.gov |
| Sep 11, 2017 | New notice | Indefinite | $2,926,888 | 70 | Dec 20, 2013 | sec.gov |
Executive officers and directors named in the filing
| Name | Role | Note in the filing |
|---|---|---|
| Shane Austin | Executive Officer | |
| Robert Erwin | Director | |
| Lon Hatamiya | Director | |
| Brian Woodall | Executive Officer | |
| Mark Holman | Executive Officer, Director | |
| Richard Fowler | Director | |
| Landon Ellis | Executive Officer | |
| Jenna Hansen | Director |
Every Form D from the week of Mar 4, 2024 · All recent Pharmaceuticals filings
Read from SEC EDGAR. Amount sold is what Expanesthetics, Inc reported on the day it filed; on an offering that is still open, a later amendment can raise it. Free to reuse with credit to SpecStream under CC BY 4.0.